MedTrace Logo

Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight

NCT00834652 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2018-09-10

Study results available
· View outcomes & findings →

Summary

This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.

Conditions

Interventions

DRUG

Sertraline

50 mg once a day, which may be increased to 200 mg once a day

DRUG

Metformin

Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Patrick J. Lustman, PhD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00834652 on ClinicalTrials.gov